Trial Profile
An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Apr 2022
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms CHORDS
- Sponsors Genentech
- 01 Apr 2022 Results assessing efficacy and safety of ocrelizumab (OCR) in patients with relapsing-remitting MS (RRMS) and suboptimal response to prior DMTs, published in the Multiple Sclerosis Journal.
- 13 Oct 2021 According to a Roche media release, subgroup analysis from of three studies (SaROD, CHORDS ENSEMBLE PLUS) in Black, African-American, Hispanic and Latino populations treated with a 2 hour OCREVUS infusion are being presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2021.
- 05 Oct 2021 According to a Roche media release, subgroup analysis from of three studies (SaROD, CHORDS ENSEMBLE PLUS) in Black, African-American, Hispanic and Latino populations treated with a 2 hour OCREVUS infusion will be presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2021.